The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Side-effects associated with ketamine use in depression: a systematic review
Open accessAbstract
This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and Cochrane Databases and identified 288 articles, 60 of which met the inclusion criteria. After acute dosing, psychiatric, psychotomimetic, cardiovascular, neurological, and other side-effects were more frequently reported after ketamine treatment than after placebo in patients with depresssion. Our findings suggest a selective reporting bias with limited assessment of long-term use and safety and after repeated dosing, despite these being reported in other patient groups exposed to ketamine (eg, those with chronic pain) and in recreational users. We recommend large-scale clinical trials that include multiple doses of ketamine and long-term follow up to assess the safety of long-term regular use.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, side effects such as ketamine-induced ulcerative cystitis and dependence may pose a concern, especially when ketamine use is frequent and of prolonged duration (Short et al., 2018;Morgan et al., 2012).”
From Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review (2022) · cites this paper as Short et al., 2018
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258
RetractedCochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,178
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Depression: A Global Public Health Concern: (517532013-004)
Marcus, M., Yasamy, M. T., van Ommeren, M. V., Chisholm, D., & Saxena, S. (2012) · PsycEXTRA Dataset · doi:10.1037/e517532013-004 · Cited by 985
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Research works printed but not linked: 7
- Worthington, 2015, Ketamine offered to patients with depression in take-home, DIY packs by controversial clinic, ABC News
- Kembrey, 2015, Medical clinics promote ketamine injections as treatment for depression, Sydney Morning Herald
- Bella, 2015, Could ketamine become the next great depression drug?, Aljazeera America
- Singh, 2013, Efficacy and safety of intravenous esketamine in patients with treatment-resistant depression: a double-blind, double-randomization, placebo controlled phase 2a study, Neuropsychopharmacology, 38, s369
- Quinones, 2012, Experience integrating ketamine into the healthcare system: outpatient and inpatient treatment of post-partum depression, suicidal ideation and comorbid chronic pain-mood disorders, Neuropsychopharmacology, 38, s442
- Kalsi, 2011, The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use, Emerg Health Threats J, 4, 7107, 10.3402/ehtj.v4i0.7107 · DOI · Paper page
- Jansen, 2000, Anaesthetic apocalypse. Ketamine part 2: addictive psychedelic, Druglink, 18
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Approximately 72% of studies with intravenous racemic ketamine in TRD report dissociation, compared with 36% in non-intravenous racemic ketamine studies, most likely reflecting differences in plasma levels rather than route of administration (79).”
BackgroundResultInfluentialAttenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Metadata
- Authors
- Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K.
- Affiliations
- Black Dog Institute (AU)
- UNSW Sydney (AU)
- University of Otago (NZ)
- Corresponding author
- Loo, Colleen K
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 5
- Issue
- 1
- Pages
- 65-78
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2741959390
- Cited by
- 558
- References
- 117
- Citations by year
- 2026: 53 · 2025: 76 · 2024: 78 · 2023: 64 · 2022: 79 · 2021: 73 · 2020: 60 · 2019: 40 · 2018: 31
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- green
- handle.unsw.edu.au
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, depression, drug safety, adverse effects, psychotomimetic effects, cardiovascular effects, neurological effects, psychiatric adverse effects, repeated dosing, long-term use, selective reporting
- MeSH terms
- Long Term Adverse Effects, Anesthetics, Dissociative, Antidepressive Agents, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Ketamine, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Side-effects associated with ketamine use in depression: a systematic review. https://app.cochat.ai/papers/10.1016/s2215-0366(17)30272-9
- The paper
- Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: a systematic review. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(17)30272-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.